Trispecific CAR T cells that target HER2, IL13Ra2, and EphA2 offer more thorough coverage of tumor antigens and have been demonstrated to considerably extend the longevity of mice, bearing glioblastoma patient-derived xenografts [48]. This evidence concerns the gene ERBB2 and neoplasm.